Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer.

Trial Profile

A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Custirsen (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors OncoGenex Technologies
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Jul 2012 Results from the phase II portion of this trial have been reported in an OncoGenex Pharmaceuticals media release.
    • 04 Jan 2012 Results published in an early online version of the Journal of Thoracic Oncology, according to an OncoGenex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top